Question explored with the scientific record
Conversation so far
- 1 does anastrazole make heart and genital muscles stiff
- 2 Are there any reports of heart problems from anastrozole besides cholesterol changes?
Answered on this page ↓
Are there any reports of heart problems from anastrozole besides cholesterol changes?
The short version: the evidence you have does not contain a single study that looked for clinical heart problems from anastrozole beyond cholesterol changes.
The records here are almost entirely about breast cancer treatment efficacy, not cardiac safety. The ATAC trial and its reviews mention that anastrozole causes more arthralgia and bone fractures than tamoxifen, but they do not report heart attacks, heart failure, arrhythmias, or any clinical cardiac event as a tracked outcome [34, 41]. One review notes anastrozole raised HDL cholesterol by about 7% but had no significant effect on LDL or triglycerides [4 from the previous answer, not in this evidence block]. That is a lipid change, not a clinical heart problem.
The evidence that does exist on heart outcomes is about entirely different drugs and populations. There are studies on statins and myocardial infarction in Sweden [7], on smoke-free legislation and heart attacks in Spain [1], on vitamin D and post-surgery atrial fibrillation [28], and on air pollution and atrial fibrillation in Beijing [23]. None of these involve anastrozole. The only anastrozole safety data in this retrieval is about joint symptoms, mood disturbance, and bone density [33, 36, 42]. No study here measured whether women on anastrozole had more heart attacks, strokes, or heart failure than women on placebo or tamoxifen.
The mechanism question matters. Anastrozole works by blocking estrogen production. Estrogen has known protective effects on blood vessels and the heart. Drastically lowering estrogen in postmenopausal women is not biologically neutral for the cardiovascular system. The absence of evidence in this retrieval is not evidence of safety. It is evidence that the question was not studied in the trials that were published.
My call: the evidence you have does not answer whether anastrozole causes clinical heart problems beyond cholesterol changes. Confidence: not clear.
Sources used 9
-
Impact of a Partial Smoke-Free Legislation on Myocardial Infarction Incidence, Mortality and Case-Fatality in a Population-Based Registry: The REGICOR Study
The study investigates the impact of the 2006 Spanish partial smoke-free legislation on acute myocardial infarction (AMI) incidence, hospitalization, mortality rates, and 28-day case-fatality in Girona, Spain, revealing a significant decrease in AMI incidence and mortality, part…
DOI: 10.1371/journal.pone.0053722 -
No connection between the level of exposition to statins in the population and the incidence/mortality of acute myocardial infarction: An ecological study based on Sweden's municipalities
This ecological study investigates the relationship between statin utilization and the incidence and mortality of acute myocardial infarction (AMI) across Swedish municipalities, finding no significant correlation despite increased statin use.
DOI: 10.1186/1477-5751-10-6 -
Effects of the short‐term exposure to ambient air pollution on atrial fibrillation
This study investigates the relationship between short-term exposure to ambient air pollution and the occurrence of atrial fibrillation (AF) in high-risk patients in Beijing, finding significant associations with particulate matter (PM2.5 and PM10) but not with other pollutants.
DOI: 10.1111/pace.13500 -
Effects of high-dose vitamin D supplementation on the occurrence of post-operative atrial fibrillation after coronary artery bypass grafting: randomized controlled trial
This randomized controlled trial investigates the effects of high-dose vitamin D supplementation on the occurrence of post-operative atrial fibrillation in patients with vitamin D deficiency or insufficiency undergoing coronary artery bypass grafting, finding that vitamin D trea…
DOI: 10.1007/s11748-019-01209-0 -
Joint symptoms: A practical problem of anastrozole
This study investigates the incidence and characteristics of joint symptoms, particularly digital stiffness, in postmenopausal women with estrogen receptor-positive breast cancer treated with anastrozole, revealing a significant occurrence of these symptoms and their potential i…
DOI: 10.2325/jbcs.13.284 -
Anastrozole: A New Gold Standard of Hormonal Treatment for Breast Cancer?
This is a comprehensive review of anastrozole as a third‑generation aromatase inhibitor for breast cancer, detailing its pharmacology, pharmacokinetics, and evidence from Phase I–III trials across adjuvant, preoperative, and advanced settings, and concluding that anastrozole gen…
DOI: 10.2217/17455057.1.3.309 -
Risk of Anastrozole-related Mood Disturbances and Dizziness among Breast Cancer Patients taking Anastrozole
Among 97 post-menopausal ER+ breast cancer patients taking anastrozole, treatment duration over three years was associated with increased odds of mood disturbance (aOR 20.31), while dizziness and serum oestrogen showed no significant associations.
DOI: 10.51658/abms.202011.1 -
Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women
In postmenopausal women with early-stage hormone-receptor-positive breast cancer, adjuvant anastrozole significantly improved disease-free survival and time to recurrence compared with tamoxifen, but was associated with more arthralgia and bone fractures and fewer gynecologic sy…
DOI: 10.4137/cmt.s9 -
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
The DATA study, a phase 3 trial, investigates the efficacy of extended anastrozole therapy after sequential tamoxifen treatment in postmenopausal women with hormone receptor-positive breast cancer, finding no significant improvement in disease-free survival with 6 years of anast…
DOI: 10.1016/S1470-2045(17)30600-9